ACS
IONS icon

Archford Capital Strategies’s Ionis Pharmaceuticals IONS Stock Holding History

Archford Capital Strategies’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,042
Closed -$223K – 283
2022
Q3 		$223K Buy
+5,042
New +$212K 0.06% 254

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Archford Capital Strategies's IONS Position: Q4 2022 in Review

Archford Capital Strategies sold out of Ionis Pharmaceuticals (IONS) in Q4 2022, closing a stake of 5,042 shares — an estimated $223K sold.

Archford Capital Strategies first reported a position in IONS in Q3 2022 and held it in 1 quarter. The position peaked at $223K in Q3 2022. 338 funds tracked by Wall St. Rank hold IONS as of Q4 2022.

  • Archford Capital Strategies reported no remaining Ionis Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Archford Capital Strategies sold 5,042 Ionis Pharmaceuticals shares in Q4 2022, an estimated $223K.
  • Archford Capital Strategies first reported a position in Ionis Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Archford Capital Strategies's Ionis Pharmaceuticals position peaked at $223K in Q3 2022.
  • 338 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2022.

Based on Archford Capital Strategies's 13F filing for Q4 2022, filed 26 Jan 2023.